Pinealon

Overview

Pinealon is a synthetic tripeptide (Glu-Asp-Arg, abbreviated EDR) developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. It sits within the Khavinson short-peptide bioregulator hypothesis, which proposes that very short peptides can influence gene expression in specific tissues. That mechanism remains a hypothesis rather than an independently replicated finding, so it is best read as a research idea, not an established fact.

The published work on pinealon is almost entirely preclinical and comes largely from a single Russian research school: in-vitro studies in rat neuronal cells and rodent models of oxidative stress, hypoxia, and brain aging report reduced reactive oxygen species and improved cell viability. Human evidence is very limited and largely non-Western, and no independent Western clinical trial has been published. This page describes what has been studied, not a recommendation to use it.

Dosing

There is no approved or Western-validated human dose for pinealon. It is investigational and studied mostly in animals, so any dose figures found online are non-Western or anecdotal and unverified.

Side effects

Pinealon's human safety profile is poorly characterized. There are no controlled Western safety data, so common and rare risks in people are essentially unknown.

Storage

Handling guidance for pinealon is not standardized because it is not a licensed product. Research peptides are generally kept refrigerated and protected from light, and lyophilized powder is typically stored frozen until reconstituted. See the full storage & safety guide for general handling and disposal basics.